Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 355 followers
Latest posts
Last updated 7 days ago
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis
7 days ago
The first (FENhance 2) of two pivotal RMS studies met its primary...
Roche to present new data from its broad and innovative haematology portfolio at ASH 2025
14 days ago
Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment...
Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus
14 days ago
Phase III ALLEGORY study met primary and all key secondary endpoints with...
Roche purchases shares in tender offer for 89bio, Inc
18 days ago
Basel, 30 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised
25 days ago
Group sales grew by 7%1 at constant exchange rates (CER; 2% in...
Reminder: Invitation to Roche’s 3rd Quarter Sales 2025 Presentation
28 days ago
Roche will publish its Sales for the 3rd Quarter of 2025 prior...
Reminder: Invitation to Roche’s 3rd Quarter Sales 2025 Presentation
28 days ago
Roche will publish its Sales for the 3rd Quarter of 2025 prior...
Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
28 days ago
Tecentriq reduced the risk of death by 41% and the risk of...
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
28 days ago
FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as...
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
about 1 month ago
Giredestrant plus everolimus reduced the risk of disease progression or death by...
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
about 1 month ago
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving...
CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis
about 1 month ago
Positive recommendation based on phase II NOBILITY and phase III REGENCY data...